Latest Information Update: 12 Aug 2002
At a glance
- Originator PowderJect Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 12 Aug 2002 Discontinued - Preclinical for Prostate cancer in USA (unspecified route)
- 27 Aug 1999 Preclinical development for Prostate cancer in USA (Unknown route)